Cizzle Biotechnology (CIZ) Ord 0.01p

Sell:1.30pBuy:1.60pNo change

Prices delayed by at least 15 minutes
Sell:1.30p
Buy:1.60p
Change:No change
Deal now
Prices delayed by at least 15 minutes
Sell:1.30p
Buy:1.60p
Change:No change
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Cizzle Biotechnology Holdings PLC is a United Kingdom-based diagnostics developer of early cancer tests. The Company is focused on early detection of lung cancer via the development of an immunoassay test for the CIZ1B biomarker. CIZ1B is a variant of CIZ1, a naturally occurring cell nuclear protein involved in protecting deoxyribonucleic acid (DNA). Its CIZ1B biomarker detects lung cancer at its earliest and most treatable stage. It is designed as a simple blood test, which enables early diagnosis before symptoms appear-when treatment options can transform outcomes for patients and families.

Key people

Allan John Syms
Executive Chairman of the Board
Nigel Lee
Finance Director, Executive Director
Dawn Coverley
Chief Scientific Officer, Executive Director
Matt Bower
Non-Executive Director
Edwin Matthew
Non-Executive Director
John Treacy
Non-Executive Independent Director
Click to see more

Key facts

  • Shares in issue
    396.39m
  • EPIC
    CIZ
  • ISIN
    GB00BNG2VN02
  • Location
    United Kingdom
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    £5.75m
  • Employees
    67
  • Exchange
    London Stock Exchange (LON)
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.